JENNIFER FOSTER to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications JENNIFER FOSTER has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
1.236
-
Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615). Eur J Cancer. 2024 Sep; 209:114241.
Score: 0.576
-
Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling. Cancer Lett. 2019 08 10; 457:129-141.
Score: 0.401
-
Factors Impacting Time to Engraftment in Patients With High-risk Neuroblastoma Following Autologous Stem Cell Transplant. J Pediatr Hematol Oncol. 2020 10; 42(7):e569-e574.
Score: 0.110
-
Using a Bedside Algorithm to Individually Dose High-dose Methotrexate for Patients at Risk for Toxicity. J Pediatr Hematol Oncol. 2017 01; 39(1):72-76.
Score: 0.085
-
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor. J Clin Oncol. 2023 01 20; 41(3):508-516.
Score: 0.032
-
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.
Score: 0.031